New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
16:25 EDTMYL, SNTSSantarus discloses lawsuit against Mylan for patent infringement
Santarus disclosed in a regulatory filing that on January 28, Santarus (SNTS) filed a lawsuit in the U.S. District Court for the District of Delaware against Mylan (MYL) and Mylan Pharmaceuticals for infringement of the patents listed in the Orange Book for Santarusí prescription product, Fenoglide tablets, 40 mg and 120 mg. Veloxis Pharmaceuticals A/S, licensor of the patents, is joined in the litigation as a co-plaintiff. The lawsuit is in response to an Abbreviated New Drug Application filed by Mylan with the U.S. FDA regarding Mylanís intent to market generic versions of Fenoglide prior to the 2024 expiration of the two listed patents. The lawsuit was commenced within the 45 days required to automatically stay, or bar, the FDA from approving Mylanís ANDA for 30 months or until a district court decision that is adverse to the plaintiffs, whichever may occur earlier.
News For SNTS;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
10:43 EDTMYLMylan calls active after called 'most likely' Pfizer takeover target
Subscribe for More Information
10:34 EDTMYLMylan advances after called 'most likely' Pfizer takeover target
Subscribe for More Information
07:48 EDTMYLMylan now most likely takeover target for Pfizer, says Jefferies
Jefferies believes Mylan (MYL), following its combination with Abbott's (ABT) Developed Markets Established Products business, is now the most likely takeover target of Pfizer (PFE). The firm thinks Pfizer management is highly motivated to either merge with, invert into or acquire a foreign company. It believes Actavis (ACT) and AstraZeneca (AZN) are off the table as potential Pfizer targets given the former's takeover of Allergan (AGN) and latter's oncology deal with Merck KGaA (MKGAY). Jefferies calls GlaxoSmithKline (GSK) the "wild card" potential takeover target for Pfizer. The firm estimates Pfizer could pay a 25% premium for Mylan and have the deal be highly accretive.
November 25, 2014
07:33 EDTMYLMylan sued by Baxter in connection with ANDA for Esmolol HCl
Subscribe for More Information
November 19, 2014
10:14 EDTMYLMylan November calls active on takeover speculation
Mylan November 55 & 57.5 calls are active on total call volume of 7,100 contracts (200 puts) on takeover speculation. November call option implied volatility is at 36, December is at 34; compared to its 26-week average of 32 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:51 EDTMYLRumor: Mylan strength attributed to takeover speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use